Blood Cancers Today
Blood Cancers Today
  • 423
  • 83 925
How Will AML Treatment Evolve?
In the final portion of this roundtable discussion at the 2024 American Society of Clinical Oncology Annual Meeting, Eric Winer, MD, of the Dana-Farber Cancer Institute; Naval Daver, MD, of the University of Texas MD Anderson Cancer Center; and Yasmin Abaza, MD, of Northwestern University, discuss what acute myeloid leukemia (AML) treatment will look like in the future.
มุมมอง: 16

วีดีโอ

Study Highlights Importance of Immunoglobulin G Screening in Patients With CLL, NHL
มุมมอง 8912 ชั่วโมงที่ผ่านมา
Jacob Soumerai, MD, an Assistant Professor of Medicine at Massachusetts General Hospital Cancer Center, discusses his study on immunoglobulin G (IgG) testing in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Patients who received at least three tests for IgG were less likely to experience severe infections compared with those who didn’t. “The findings were inte...
Prithviraj Bose, MD, Talks Novel Myelofibrosis Therapies
มุมมอง 47วันที่ผ่านมา
Dr. Bose, of the University of Texas MD Anderson Cancer Center, discusses the novel therapies in myelofibrosis (MF) he is most excited about. “MF is clearly a bigger unmet need,” he began. “Median survival is still in the range of six-and-a-half to seven years.” New therapies, such as TP-3654, are currently being explored in combination studies. “[TP-3654] is now entering combination studies wi...
Lore Gruenbaum, PhD, Discusses the LLS Therapy Acceleration Program
มุมมอง 64วันที่ผ่านมา
Dr. Gruenbaum, Vice President of the Therapy Acceleration Program at the Leukemia & Lymphoma Society (LLS), discusses the program’s goals and initiatives at the European Hematology Association 2024 Congress. The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies. “We bring the perspective of the patient and our understanding of the scie...
Beat AML Trial to Expand into MDS Therapy
มุมมอง 99วันที่ผ่านมา
At the European Hematology Association 2024 Congress, Lore Gruenbaum, PhD, Vice President of the Therapy Acceleration Program at the Leukemia & Lymphoma Society, discusses the Beat AML trial in acute myeloid leukemia and its expansion into myelodysplastic syndromes (MDS) therapy. Since 2016, the Beat AML trial has provided practice-changing insights such as the ability to incorporate genetic pr...
Dr. Martin Highlights Recent Myeloma Research at EHA 2024
มุมมอง 121วันที่ผ่านมา
Thomas Martin, MD, Clinical Research Director of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses exciting research in newly diagnosed multiple myeloma (MM) presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. Specifically, Dr. Martin highlighted research in quadruplet therapy, chimeric antigen recep...
Thomas Martin, MD, Looks Forward to SOHO 2024
มุมมอง 18วันที่ผ่านมา
Dr. Martin, Clinical Research Director of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, which will take place September 4-7, 2024, in Houston, Texas. “We're going to have a great session on multiple myeloma,” Dr. Martin said. “We're going to include discussions about [chimer...
Dr. Manier Discusses Initial Data From MajesTEC-7 Phase III Trial at EHA 2024
มุมมอง 35วันที่ผ่านมา
Salomon Manier, MD, PhD, Associate Professor of Hematology at Lille University Hospital in France, spoke to Blood Cancers Today of the safety run-in results for cohort one of the phase III MajesTEC-7 study. These results were presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. These particular data from MajesTEC-7 demonstrated that the combination of te...
Treatment Strategies in Older Patients With AML
มุมมอง 5714 วันที่ผ่านมา
In a roundtable discussion at the 2024 American Society of Clinical Oncology Annual Meeting, Eric Winer, MD, of the Dana-Farber Cancer Institute; Naval Daver, MD, of the University of Texas MD Anderson Cancer Center; and Yasmin Abaza, MD, of Northwestern University, discuss how their centers treat older patients with acute myeloid leukemia (AML). - Dr. Winer: Now that we’ve talked about the you...
Dr. Willekens Presents Efficacy Findings for Reduced-Dose Venetoclax in AML
มุมมอง 3614 วันที่ผ่านมา
Christophe Willekens, MD, of the Gustave Roussy Cancer Center in France, met with Blood Cancers Today at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain. He described his retrospective study comparing venetoclax dosing regimens in patients with acute myeloid leukemia (AML), which he presented at the Congress. Dr. Willekens’ study involved a cohort of patients who recei...
Dr. Lentzsch on the LINKER-MM1 Study Presented at EHA 2024
มุมมอง 5114 วันที่ผ่านมา
Suzanne Lentzsch, MD, PhD, of Columbia University, describes the LINKER-MM1 study on linvoseltamab in patients with relapsed or refractory multiple myeloma (MM) presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. The investigational bispecific antibody achieved an overall response rate of 71%. Half (50%) of the patients achieved a complete response (CR)...
GAIA/CLL13 Trial Follow-Up Compares Venetoclax Combinations in CLL
มุมมอง 7314 วันที่ผ่านมา
Moritz Fürstenau, MD, of the University of Cologne, discusses his recent study on venetoclax combinations versus chemoimmunotherapy in patients with chronic lymphocytic leukemia (CLL). Both the venetoclax plus obinutuzumab doublet and the venetoclax, obinutuzumab, and ibrutinib triplet were associated with longer progression-free survival compared with the chemoimmunotherapy and venetoclax plus...
Study Compares HSCT Outcomes in Rare T-Cell Lymphoma Subtype
มุมมอง 7214 วันที่ผ่านมา
Hemant Murthy, MD, an Associate Professor of Medicine at the Mayo Clinic in Florida, discusses his study on hematopoietic stem cell transplantation (HSCT) outcomes in patients with hepatosplenic T-cell lymphoma. The study found no significant differences in overall survival or progression-free survival between allogeneic HSCT and autologous HSCT. “[HSCT] is an effective treatment that can prolo...
Dr. Berenson on the Myeloma BioBank Launch
มุมมอง 7914 วันที่ผ่านมา
Blood Cancers Today spoke with James Berenson, MD, of the Berenson Cancer Center, about the launch of the Myeloma BioBank. "We've been very interested in figuring out how to better predict outcomes in myeloma," Dr. Berenson said. "In order to do that, we have been collecting bone marrow and blood specimens from myeloma patients for the last two decades to better be able to determine their outco...
Dr. Oluwole on Long-Term Brexu-Cel Outcomes in ZUMA-3
มุมมอง 10221 วันที่ผ่านมา
At the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, Blood Cancers Today met with Olalekan Oluwole, MD, of the Vanderbilt University Medical Center, to hear data from the phase II ZUMA-3 trial on brexucabtagene autoleucel (brexu-cel) in patients with relapsed or refractory acute lymphoblastic leukemia. “Some of the earlier presentations demonstrated the respons...
PERSEUS Data Support Daratumumab as New Standard of Care for Myeloma
มุมมอง 6028 วันที่ผ่านมา
PERSEUS Data Support Daratumumab as New Standard of Care for Myeloma
Top Three Questions for MPN Researchers With Dr. Pemmaraju
มุมมอง 3928 วันที่ผ่านมา
Top Three Questions for MPN Researchers With Dr. Pemmaraju
Salomon Manier, MD, PhD, Sees Promising Therapy Data in Elderly Patients With Myeloma
มุมมอง 5928 วันที่ผ่านมา
Salomon Manier, MD, PhD, Sees Promising Therapy Data in Elderly Patients With Myeloma
Dr. Kamdar Shares Liso-Cel Data From TRANSCEND-MCL Study
มุมมอง 69หลายเดือนก่อน
Dr. Kamdar Shares Liso-Cel Data From TRANSCEND-MCL Study
Dr. Jabbour on the 2024 SOHO Annual Meeting
มุมมอง 47หลายเดือนก่อน
Dr. Jabbour on the 2024 SOHO Annual Meeting
What Is the Impact of JAK2 Allele Burden in Patients With Myelofibrosis?
มุมมอง 66หลายเดือนก่อน
What Is the Impact of JAK2 Allele Burden in Patients With Myelofibrosis?
Elias Jabbour, MD, on 2024 MDS Highlights
มุมมอง 60หลายเดือนก่อน
Elias Jabbour, MD, on 2024 MDS Highlights
What Important Breakthroughs Are Needed in AML Treatment?
มุมมอง 188หลายเดือนก่อน
What Important Breakthroughs Are Needed in AML Treatment?
The Current State of Emavusertib in AML Therapy
มุมมอง 83หลายเดือนก่อน
The Current State of Emavusertib in AML Therapy
Guillermo Garcia-Manero, MD, Looks Ahead to SOHO 2024
มุมมอง 30หลายเดือนก่อน
Guillermo Garcia-Manero, MD, Looks Ahead to SOHO 2024
Tycel Phillips, MD, Shares Glofitamab Data in MCL
มุมมอง 75หลายเดือนก่อน
Tycel Phillips, MD, Shares Glofitamab Data in MCL
What Are The Biggest Breakthroughs in AML Treatment?
มุมมอง 137หลายเดือนก่อน
What Are The Biggest Breakthroughs in AML Treatment?
Experts Outline Treatment Algorithms for AML With the Latest Data
มุมมอง 88หลายเดือนก่อน
Experts Outline Treatment Algorithms for AML With the Latest Data
Raajit Rampal, MD, PhD, on Bone Marrow Recovery in the Manifest-2 Trial
มุมมอง 63หลายเดือนก่อน
Raajit Rampal, MD, PhD, on Bone Marrow Recovery in the Manifest-2 Trial
How Quadruplet Therapy Is Changing the Myeloma Treatment Landscape
มุมมอง 396หลายเดือนก่อน
How Quadruplet Therapy Is Changing the Myeloma Treatment Landscape

ความคิดเห็น

  • @varunas2565
    @varunas2565 13 ชั่วโมงที่ผ่านมา

    Please save this world from AML, lots of adults and small children are suffering from this deadly disease

  • @AB2008.
    @AB2008. 5 วันที่ผ่านมา

    Can you have VSG AFTER having Multiple Myeloma?

  • @El_pilou
    @El_pilou 7 วันที่ผ่านมา

    thx Dr. Cortes you give me hope

  • @shubhamsoni9802
    @shubhamsoni9802 21 วันที่ผ่านมา

    Is their anychance to stop medicine

  • @shubhamsoni9802
    @shubhamsoni9802 21 วันที่ผ่านมา

    How cure cab be define

  • @clarkbennett2312
    @clarkbennett2312 หลายเดือนก่อน

    I have AML and am 68. Will be going in next month for a clinical trial induction, and then the transplant. Wish me luck😊

    • @amira2736
      @amira2736 28 วันที่ผ่านมา

      good luck!

  • @elenascopelliti1211
    @elenascopelliti1211 หลายเดือนก่อน

    My experience with Pelabresib was terrible and I still have to deal with serious conseguencies. I was enrolled in MANIFEST-2 protocol in Rome. My life became miserable because I was always ill. I stopped after the virus herpes zoster was reactivated and I suffered a sever facial paralysis and horrible balance problems. After one year I still have a parcial paralysis and balance problems because the VII and VIII cranial nerves were severy injured. I accepted to be enrolled because the doctor told me that otherwise I was going to die for leukemia. That was not true! I didn't even have the intermediate-1 grade of myelofibrosis! I only had pre-myelofibrosis! Now I am well cured for pre-myelofibrosis in another roman hospital, only with oncocarbide, cardioaspirin and booldlettings when necessary, exactly as before I was enrolled in Manifest-2 sperimental protocol. I have never have anemia, sweeting or other sintoms, except a bit of fatigue. I've spent 10 thousand euros for the cures. Recently I've filed a lawsuit against the hospital. But the law in Italy is really slow and I'll wait 10 years to have justice. The bad news is that I am hughly and parcial disabled, the good news is that I'm not going to die soon as I was told by the doctor who enrolled me in MANIFEST-2!

  • @judithwhite1
    @judithwhite1 หลายเดือนก่อน

    Thank you so much (drotsiherbalcure) for the difference you make in the lives of your patients! Your kindness, sincere caring, treatment and concern make everything better and you are a great encouragement to humanity. Keep saving lives Dr. thanks for curing my Herpes virus.....

  • @judithwhite1
    @judithwhite1 หลายเดือนก่อน

    Thank you so much (drotsiherbalcure) for the difference you make in the lives of your patients! Your kindness, sincere caring, treatment and concern make everything better and you are a great encouragement to humanity. Keep saving lives Dr. thanks for curing my Herpes virus...

  • @elenascopelliti1211
    @elenascopelliti1211 หลายเดือนก่อน

    My experience with Pelabresib was terrible and I still have to deal with serious conseguencies. I was enrolled in MANIFEST-2 protocol in Rome. My life became miserable because I was always ill. I stopped after the virus herpes zoster was reactivated and I suffered a sever facial paralysis and horrible balance problems. After a year I already have a parcial paralysis and balance problems because the VII and VIII cranial nerves were severy injured. I accepted to be enrolled because the doctor told me that otherwise I was going to die for leukemia. That was not true! I didn't even have the intermediate-1 grade of myelofibrosis! I only had pre-myelofibrosis! Now I am well cured for pre-myelofibrosis in another roman hospital, only with oncocarbide and booldlettings when necessary, exactly as before I was enrolled in Manifest-2 sperimental protocol. I have never have anemia, sweeting or other sintoms, except a bit of fatigue. I've spent 10 thousand euros for the cures. Recently I've filed a lawsuit against the hospital. But the law in Italy is really slow and I'll wait 10 years to have justice. The bad news is that I am hughly and parcial disabled, the good news is that I'm not going to die soon as I was told by the doctor who enrolled me in MANIFEST-2!

  • @naher852
    @naher852 หลายเดือนก่อน

    I recently viewed your TH-cam videos and was impressed by the high quality of your content. However, I noticed that they are not optimized for SEO, which may be affecting your views and subscribers. I can help you identify and fix these issues to reach your audience more effectively. Let's work together to take your channel to the next level!

  • @naher852
    @naher852 2 หลายเดือนก่อน

    Dear I see you have uploaded videos today too but your video views are getting very low, there are some problems in your channel if you fix them you will get good views, can we talk?

  • @747rld
    @747rld 2 หลายเดือนก่อน

    My wife has PV and is only 30 yrs old. Her condition is worsening. We are in northern CA with limited medical resources. The doctors at UC Davis prescribed her blood thinners but that’s it. They won’t take her on, they say her case is too severe. She now has an enormous spleen that has induced a large hernia. And she’s on extreme amounts of pain every day… they won’t fix the hernia because of the other issues related to the PV. Can someone from the east coast please help my wife before it’s too late

    • @rlove3222
      @rlove3222 2 หลายเดือนก่อน

      David is a pv patient in North Carolina

    • @rlove3222
      @rlove3222 2 หลายเดือนก่อน

      David Wallace is the website owner and a pv patient

    • @rlove3222
      @rlove3222 2 หลายเดือนก่อน

      Pv. Reporter. Com.

    • @rlove3222
      @rlove3222 2 หลายเดือนก่อน

      Pv

    • @rlove3222
      @rlove3222 2 หลายเดือนก่อน

      Reporter

  • @MediMediMary
    @MediMediMary 2 หลายเดือนก่อน

    Nobody can hear anything in this video. Get a better mic or a videographer who knows what they're doing. This is absolute nonsense.

  • @didierlason6453
    @didierlason6453 3 หลายเดือนก่อน

    This doctor has no business treating rare non-cancerous blood diseases like aplastic anemia that she is not an expert in. Peace.

  • @georgewood5634
    @georgewood5634 3 หลายเดือนก่อน

    Promo>SM 💞

  • @TheBeatlesGuiseDuo
    @TheBeatlesGuiseDuo 3 หลายเดือนก่อน

    Dr Wang, your passion to successfully treat MCL is so apparent and so appreciated. After listening to several of your broadcasts I am wondering if your Ibrutinib Plus Venetoclax treatment is or can be used for patients who are not young, are older than 70? I'm only extrapolating after listening to hearing an emphasis on young patients mentioned particularly. I know someone just getting chemo for MCL and not reacting well to it. Would like to help them.

  • @Chad-Giga.
    @Chad-Giga. 3 หลายเดือนก่อน

    Respect for your accomplishments in academia, but the cancer industry is truly rampant with profiteering and dangerous therapies which harm the patient more than help them. I think back to the little girl who was cured of brain cancer through radiation treatment, so she beat the cancer, but she also died a few months later because her brain literally fell apart due to the damage from the radiation. Medicine is supposed to be a risk vs reward system, not a system of capitalism and torture. It is morally wrong to prolong somebody's life just so you can experiment on them or make a profit from them. It is reprehensible.

  • @chief270202
    @chief270202 3 หลายเดือนก่อน

    Mark, do you promote taking Iodine? It's a large reason so many people have cancer, and thyroid issues, because you Doctors promote drugs instead of therapy that actually gets rid of the cancer naturally

  • @orscrub3161
    @orscrub3161 4 หลายเดือนก่อน

    Sadly, it did not work for my husband. As a matter of fact, in less than 6 months his MM progressed to PCL.

    • @JesusSanchez-xu2is
      @JesusSanchez-xu2is 2 หลายเดือนก่อน

      How old was your husband? Also did he receive a ASCT prior to this?

    • @orscrub3161
      @orscrub3161 2 หลายเดือนก่อน

      @@JesusSanchez-xu2is ….52 when dx and 66 when he passed. He had an auto SCT at the very beginning. And a SCT from his sister in the end

  • @marshiathomas8804
    @marshiathomas8804 4 หลายเดือนก่อน

    What is considered high risk and short remissions?? Please, my son has MM and I am TERRIFIED!! Marshia in Charlotte NC

  • @serferten
    @serferten 5 หลายเดือนก่อน

    It would help to clarify what specific stages or levels of response would work with say less therapy. I've responded very well it seems and less might work well for me.

  • @rohitchauhan-nj1oh
    @rohitchauhan-nj1oh 5 หลายเดือนก่อน

    Hindi

  • @sampathsam2610
    @sampathsam2610 6 หลายเดือนก่อน

    Mrd negative means it cured

  • @Ourania.b
    @Ourania.b 6 หลายเดือนก่อน

    If you had an AML patient with mutations IDH2, SF3B1, ASXL1, NPM1 and a history of heart disease would you choose low intensity chemo with a menin inhibitor or high intensity chemo with a menin inhibitor?

  • @MirzaYasir-ww6tn
    @MirzaYasir-ww6tn 6 หลายเดือนก่อน

    Rite

  • @Denise-ux4xd
    @Denise-ux4xd 6 หลายเดือนก่อน

    Aiders & Abetters of W@r Crimes are equally guilty.

  • @jrobson382
    @jrobson382 6 หลายเดือนก่อน

    timely , finally

  • @hunnybadger442
    @hunnybadger442 6 หลายเดือนก่อน

    It's already too late for me

  • @MicaCardillo
    @MicaCardillo 7 หลายเดือนก่อน

    I'm hoping we can find a better proxy than the current MRD testing. For one, it seems cost prohibitive. We need to be able to do something like monthly testing to really understand the response, and my naive instinct is that MRD is more than just ratio of abnormal Bs. I suspect that if we could cost effectively survey the immune system on a monthly basis, like a flow panel that gives us more information about subsets, especially t subsets, there is probably a signal that deep learning could uncover. Plus, t cell exhaustion is something I'd like to better understand. How do we treat that problem? Maybe by being more selective, or attinuating dosage based on t cell exhaustion?

  • @MicaCardillo
    @MicaCardillo 7 หลายเดือนก่อน

    Much appreciated update. Thank you!

  • @rodro7620
    @rodro7620 7 หลายเดือนก่อน

    Fantastic discussion 👏😁👏👏👏👏

  • @pauldodd2120
    @pauldodd2120 8 หลายเดือนก่อน

    Strange not to mention the drug and type of drug in an introduction...

  • @user-xv3kr8hw7g
    @user-xv3kr8hw7g 8 หลายเดือนก่อน

    If my mrd is negative.Still I need transplant?

  • @JesusSanchez-xu2is
    @JesusSanchez-xu2is 8 หลายเดือนก่อน

    I've never been overweight. I've worked out my entire life. I was muscular. I have MM.

  • @JesusSanchez-xu2is
    @JesusSanchez-xu2is 8 หลายเดือนก่อน

    Why not do CAR-T first line for everyone? It's safer and more effective than BMT and doesn't require maintenance.

  • @JesusSanchez-xu2is
    @JesusSanchez-xu2is 9 หลายเดือนก่อน

    Will this be available first line instead of ASCT.

  • @Lakridza67
    @Lakridza67 9 หลายเดือนก่อน

    She really is brilliant. Dr Maryann helped with my transplant for AML and I’m still here! Absolute treasure of a Doctor👏👏💯

  • @mdrahamatullahmd4574
    @mdrahamatullahmd4574 10 หลายเดือนก่อน

    I am a c l l blood cancer patient. I am battling with this disease since one year. I am consuming tablet ibrutinib daily. Every thing is going on well but my bodyweight is gradually decreasing. Please give suggestion how can i live well.

  • @bekincai
    @bekincai 10 หลายเดือนก่อน

    so why is Curis trading below cash?

  • @may_laytrucker3127
    @may_laytrucker3127 ปีที่แล้ว

    Dr Richard is excellent Dr ,she treat my wife leukemia ,and she's cured also in 13 year's remission.!

  • @ardengoglia8034
    @ardengoglia8034 ปีที่แล้ว

    😚 "Promo SM"

  • @Marie.Helms3
    @Marie.Helms3 ปีที่แล้ว

    Hey Dr. Usmani. You are missed in Charlotte, NC.

  • @susantasaha
    @susantasaha ปีที่แล้ว

    Congratulations 💐

  • @marcweill4387
    @marcweill4387 ปีที่แล้ว

    He is detailed and precise in ways that are required to understand Round up harming everyone.

  • @mariomoody3683
    @mariomoody3683 ปีที่แล้ว

    ρɾσɱσʂɱ ✨

  • @medicalscienceadda
    @medicalscienceadda ปีที่แล้ว

    nice presentation doctor

  • @joeeastwood3795
    @joeeastwood3795 2 ปีที่แล้ว

    How do the B-Cells do on the fixed duration treatment.Do they recover?